Bryant Furlow

Bryant Furlow

Contributing Writer https://www.oncologynurseadvisor.com
Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a BS in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research and health care policy. Prior to joining Haymarket in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.

All articles by Bryant Furlow

Researchers are seeking genetic biomarkers that can predict which patients are most likely to suffer radiotoxicities and which can safely undergo intensified radiation treatment regimens.

Recent research implicates patients’ immune cells appear to stimulate radiation abscopal effects, raising the possibility that combining radiotherapy and immunotherapy could yield previously-untapped treatment synergies to improve tumor control.